What the changes say
- Edwards added explicit warnings regarding AI utilization and public health crises.
- Competition risks now cite hospital staffing and facility constraints.
- The Critical Care product group sale continues under interim operating models.
What changed since the prior 10-K
New
- NewBusiness and Operating Risks
We are subject to risks associated with public health crises
Future public health crises or pandemics could disrupt hospital systems, supply chains, and our business operations.
- NewBusiness and Operating Risks
Our use of, or our failure to effectively and timely utilize, emerging technologies, including AI, could adversely impact our business and financial results
The use of emerging technologies like AI introduces regulatory, cybersecurity, privacy, and competitive risks if not managed effectively.
- NewBusiness and Operating Risks
We may be adversely impacted by global economic, political and social conditions
Global macroeconomic conditions, tax changes, tariffs, and interest rates could negatively impact our business and customers.
- NewBusiness and Operating Risks
Our international operations subject us to certain business risks
International operations expose us to tariffs, trade protection measures, currency fluctuations, and foreign regulatory scrutiny.
- NewLegal, Compliance, and Regulatory Risks
Health care legislation and other regulations may adversely impact access to and demand for our products
Healthcare legislation like the Affordable Care Act and Swiss-EU medical device regulations could impact procedure volumes and product access.
- NewLegal, Compliance, and Regulatory Risks
We are subject to litigation, investigations, and other legal proceedings relating to our products, customers, competitors, and government regulators that could materially adversely affect our financial condition, divert management’s attention, and harm our business
Legal proceedings and investigations could result in significant monetary damages, legal costs, and diversion of management attention.
Dropped
- DroppedBusiness and Operating Risks
We are subject to risks associated with public health crises, particularly with respect to the pressures that such crises create on the hospital systems and supply chains in which we operate
- DroppedBusiness and Operating Risks
Our extensive global operations and business activity as well as the fact that many of our manufacturing facilities and suppliers are outside of the United States expose us to certain financial, economic, political, and other risks, including those listed below
- DroppedLegal, Compliance, and Regulatory Risks
In addition, third parties could also obtain patents that may require us to either redesign products or negotiate licenses from such third parties, which may be costly, unavailable, or require us to exit a particular product offering
Reworded
- 42% rewrittenBusiness and Operating Risks
Failure to successfully integrate acquired businesses, technologies or strategic alliances, or challenges related to the execution of acquisitions or divestitures, as well as liabilities or claims relating to such acquired businesses or divestitures, could adversely affect our business and results of operations
Minor phrasing refinements made to integration risks regarding acquired businesses and structural heart therapies.
- 37% rewrittenLegal, Compliance, and Regulatory Risks
Third parties may claim we are infringing their intellectual property, and we could suffer significant litigation or licensing expenses or be prevented from selling products
Removed a reference pointing readers to Note 20 of the Consolidated Financial Statements regarding ongoing patent litigation.
- 34% rewrittenBusiness and Operating Risks
We operate in highly competitive markets, and if we do not compete effectively, our business will be harmed
Added a specific note that Edwards is experiencing constrained procedure volumes because multiple products compete for the same hospital facilities and staffing.
- 33% rewrittenBusiness and Operating Risks
The success of many of our products depends upon certain key physicians, research institutions, and hospital systems
Minor formatting adjustments made regarding key physicians and research institutions.
- 33% rewrittenBusiness and Operating Risks
We are subject to risks associated with the sale of our Critical Care product group
Updated to reflect ongoing operations under interim operating model arrangements following the September 3, 2024 sale of the Critical Care product group to Becton, Dickinson and Company.
- 33% rewrittenBusiness and Operating Risks
Failure to successfully innovate and develop new and differentiated products in a timely manner and effectively market these products could have a material effect on our prospects
Removed the word 'timely' before innovation and development in the risk body.
- 32% rewrittenLegal, Compliance, and Regulatory Risks
We face a number of risks related to our income taxes in the United States as well as other jurisdictions
Retained existing tax risk factors with minor subheading formatting adjustments.
Was: Taxes. We are subject to income taxes in the United States as well as other jurisdictions
- 31% rewrittenBusiness and Operating Risks
If government or other third-party payors decline to reimburse our customers for our products or impose other cost containment measures to reduce reimbursement levels, our ability to profitably sell our products will be harmed
Adjusted language on customer reimbursement to state that availability affects purchases and could impact pricing rather than specifying prices they are willing to pay.
Was: If government and other third-party payors decline to reimburse our customers for our products or impose other cost containment measures to reduce reimbursement levels, our ability to profitably sell our products will be harmed
- 21% rewrittenBusiness and Operating Risks
If we or one of our suppliers or logistics partners encounters manufacturing, logistics, safety, or quality problems, our business could be materially adversely affected
All 27 risk factors
Headings as the filing states them, in filing order.
Business and Operating Risks
- 01Failure to successfully innovate and develop new and differentiated products in a timely manner and effectively market these products could have a material effect on our prospects33% rewritten
- 02Unsuccessful clinical trials or procedures relating to products could have a material adverse effect on our prospects
- 03If we or one of our suppliers or logistics partners encounters manufacturing, logistics, safety, or quality problems, our business could be materially adversely affected21% rewritten
- 04We operate in highly competitive markets, and if we do not compete effectively, our business will be harmed34% rewritten
- 05The success of many of our products depends upon certain key physicians, research institutions, and hospital systems33% rewritten
- 06We are subject to risks associated with public health crisesNew
- 07We rely on third parties in the design, manufacture, and sterilization of our products. Any failure by or loss of a vendor could result in delays and increased costs, which may adversely affect our business
- 08Our use of, or our failure to effectively and timely utilize, emerging technologies, including AI, could adversely impact our business and financial resultsNew
- 09Failure to protect our information technology infrastructure and our products against cybersecurity attacks, network security breaches, service interruptions, or data corruption could materially disrupt our operations and adversely affect our business and operating results
- 10Our business and results of operations may be adversely affected if we are unable to recruit and retain qualified talent or are otherwise unsuccessful in the execution of our management succession plans
- 11Failure to successfully integrate acquired businesses, technologies or strategic alliances, or challenges related to the execution of acquisitions or divestitures, as well as liabilities or claims relating to such acquired businesses or divestitures, could adversely affect our business and results of operations42% rewritten
- 12We are subject to risks associated with the sale of our Critical Care product group33% rewritten
- 13We may be adversely impacted by global economic, political and social conditionsNew
- 14Our international operations subject us to certain business risksNew
- 15If government or other third-party payors decline to reimburse our customers for our products or impose other cost containment measures to reduce reimbursement levels, our ability to profitably sell our products will be harmed31% rewritten
- 16Continued consolidation in the health care industry could have an adverse effect on our sales and results of operations
Legal, Compliance, and Regulatory Risks
- 17Our inability to protect our intellectual property or failure to maintain the confidentiality and integrity of data or other sensitive company information, by cyber-attack or other event, could have a material adverse effect on our business
- 18Third parties may claim we are infringing their intellectual property, and we could suffer significant litigation or licensing expenses or be prevented from selling products37% rewritten
- 19Health care legislation and other regulations may adversely impact access to and demand for our productsNew
- 20We face a number of risks related to our income taxes in the United States as well as other jurisdictions32% rewritten
- 21Failure to comply with data privacy and security laws could have a material adverse effect on our business
- 22We may incur losses from product liability or other claims that could adversely affect our operating results
- 23We are subject to litigation, investigations, and other legal proceedings relating to our products, customers, competitors, and government regulators that could materially adversely affect our financial condition, divert management’s attention, and harm our businessNew
- 24Use of our products in unapproved circumstances could expose us to liabilities
- 25Our operations are subject to environmental, health, and safety regulations that could result in substantial costs
- 26Climate change, or legal, regulatory or market measures to address climate change, may materially adversely affect our financial condition and business operations
- 27We are subject to risks arising from concerns and/or regulatory actions relating to animal-borne illnesses, including “mad cow disease.”
Other Edwards Lifesciences 10-Ks
- FY2024 10-K risk factors24 risks
Edwards Lifesciences faces critical operational risks driven by medical device innovation demands, complex clinical trials, and strict global regulatory environments. Transition risks from the Critical Care product group sale and intense healthcare market competition dominate the disclosures.
Filed Feb 28, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.